BTIG Research Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price

Kymera Therapeutics (NASDAQ:KYMR) had its price objective upped by equities researchers at BTIG Research from $134.00 to $139.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research‘s target price suggests a potential upside of 13.38% from the company’s previous close.

Other research analysts have also issued reports about the stock. Barclays lifted their price objective on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. TD Cowen upgraded Kymera Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Brookline Capital Markets reaffirmed a “buy” rating on shares of Kymera Therapeutics in a report on Thursday. Wells Fargo & Company lifted their price target on Kymera Therapeutics from $116.00 to $151.00 and gave the company an “overweight” rating in a research report on Thursday, August 27th. Finally, Wolfe Research upgraded Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $180.00 price objective on the stock in a research note on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $137.32.

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock traded up $0.09 on Thursday, hitting $122.60. The company had a trading volume of 1,045,347 shares, compared to its average volume of 748,981. The stock has a market capitalization of $10.19 billion, a price-to-earnings ratio of -37.84 and a beta of 1.98. Kymera Therapeutics has a 1 year low of $55.66 and a 1 year high of $130.05. The stock has a 50 day moving average of $114.92 and a 200-day moving average of $95.84.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, October 29th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by ($0.06). Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. During the same period in the prior year, the business earned ($0.94) earnings per share. Kymera Therapeutics’s quarterly revenue was up .0% compared to the same quarter last year. Equities analysts anticipate that Kymera Therapeutics will post -3.85 earnings per share for the current year.

Insider Activity

In other news, CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $113.80, for a total value of $3,414,000.00. Following the transaction, the chief executive officer owned 666,568 shares in the company, valued at approximately $75,855,438.40. The trade was a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Brian Adams sold 6,371 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $116.83, for a total value of $744,323.93. Following the completion of the sale, the insider directly owned 50,254 shares of the company’s stock, valued at approximately $5,871,174.82. This trade represents a 11.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 15.98% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

Institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC lifted its holdings in Kymera Therapeutics by 27.5% in the 2nd quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock worth $52,000 after buying an additional 98 shares during the period. IFP Advisors Inc raised its holdings in shares of Kymera Therapeutics by 236.5% during the third quarter. IFP Advisors Inc now owns 737 shares of the company’s stock valued at $82,000 after acquiring an additional 518 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Kymera Therapeutics by 56.3% in the first quarter. PNC Financial Services Group Inc. now owns 1,285 shares of the company’s stock worth $107,000 after acquiring an additional 463 shares during the period. Empowered Funds LLC bought a new stake in Kymera Therapeutics in the first quarter valued at $203,000. Finally, Nykredit A S bought a new stake in Kymera Therapeutics in the second quarter valued at $207,000.

Trending Headlines about Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Promising KT-579 Phase 1 results: Kymera reported deep and sustained IRF5 degradation, strong modulation of disease-relevant biomarkers and a favorable safety profile in healthy volunteers. The data support further development of KT-579 as an oral treatment for immunological diseases. Kymera Therapeutics third-quarter results and KT-579 trial release
• Positive Sentiment: Analyst remains constructive: Morgan Stanley reportedly expects KYMR’s stock price to rise, providing some support for investor sentiment following the clinical update. Morgan Stanley analyst view
• Neutral Sentiment: KT-621 remains an investor focus: Preview coverage highlighted the company’s KT-621 program ahead of the earnings release, but the supplied reports do not provide new efficacy or regulatory data for the program. Kymera Therapeutics earnings preview
• Negative Sentiment: Quarterly loss exceeded expectations: Kymera reported a third-quarter loss of $1.32 per share, worse than the $1.26 consensus estimate and below the $0.94 loss recorded a year earlier. Revenue was essentially flat year over year, offering little financial offset to continued research and development spending. Kymera Therapeutics third-quarter financial results
• Negative Sentiment: Net loss widened: The broader earnings coverage reinforced the deteriorating profitability trend, with a negative net margin and no near-term earnings support. Investors may therefore remain sensitive to clinical execution, pipeline progress and cash-burn expectations. Kymera Therapeutics Q3 net loss widened

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.